Table 2. Clinical characteristics of... | Rockefeller University Press

Table 2.

Clinical characteristics of patients in MIS-C study

	Acute MIS-C^{^a}	Acute COVID-19
Severity, n (%)
MIS-C mild	17 (46%)	n/a
MIS-C moderate	10 (27%)	n/a
MIS-C severe	10 (27%)	n/a
Respiratory failure	9 (24%)	10 (63%)
ARDS	4 (11%)	5 (31%)
ECMO	0 (0%)	2 (13%)
Survival	37 (100%)	15 (94%)
Treatment, n (%)
Steroids	37 (100%)	11 (69%)
IVIG	36 (97%)	0 (0%)
Remdesivir	1 (3%)	9 (56%)
Immune modulator^{^b}	8 (21%)	0 (0%)

	Acute MIS-C^{^a}	Acute COVID-19
Severity, n (%)
MIS-C mild	17 (46%)	n/a
MIS-C moderate	10 (27%)	n/a
MIS-C severe	10 (27%)	n/a
Respiratory failure	9 (24%)	10 (63%)
ARDS	4 (11%)	5 (31%)
ECMO	0 (0%)	2 (13%)
Survival	37 (100%)	15 (94%)
Treatment, n (%)
Steroids	37 (100%)	11 (69%)
IVIG	36 (97%)	0 (0%)
Remdesivir	1 (3%)	9 (56%)
Immune modulator^{^b}	8 (21%)	0 (0%)

ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

Includes clinical data for acute presentation even if no biologic sample obtained.

All patients received Anakinra.